4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow CCX140-B: new trials by email Literature Review of CCX140-B trials Research Report on CCX140-B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome CCX140-B - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Amgen | 5 | 2018-10-01 | 2025-03-17 |
| A Study of CCX140-B in Subjects With FSGS Placebo, CCX140-B - FSGS, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Amgen | 46 | 2018-05-17 | 2025-03-13 |
| A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Placebo, CCX140-B - Diabetic Nephropathy, Type 2 Diabetes Mellitus | Phase 2 | Completed | Amgen | 332 | 2011-10-01 | 2025-02-27 |
| A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Placebo, CCX140-B - Diabetic Nephropathy, Type 2 Diabetes Mellitus | Phase 2 | Completed | Amgen | 20 | 2011-09-01 | 2025-02-27 |
| A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus Placebo, pioglitazone, CCX140-B - Type 2 Diabetes Mellitus | Phase 2 | Completed | Amgen | 159 | 2010-01-01 | 2025-03-06 |
Diabetes Mellitus, Type 2 (3) · Diabetic Nephropathies (2) · Glomerulosclerosis, Focal Segmental (2) · Proteinuria (1)
Amgen (5)
Australia (2) · Czechia (2) · Germany (2) · Hungary (2) · New Zealand (2) · Poland (2) · United Kingdom (2) · United States (2) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1)